Trial · NCT05622890
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
NCT05622890, Phase 3, Unknown, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer. Trials, record NCT05622890. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05622890
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
- NCT number
- NCT05622890
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine
- First posted
- 2022-11-21
- Last updated
- 2022-11-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Up to 2 years | Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the BIRC. |
| Secondary | Duration of response (DOR) | Up to 2 years | The time interval from initial response (CR or PR) assessed by the investigator and the BIRC to progressive disease (PD) assessed by the BIRC |
| Secondary | ORR assessed by the investigator | Up to 2 years | The best response of CR or PR assessed by the investigator. |
| Secondary | DOR assessed by the investigator | Up to 2 years | The time interval from initial response (CR or PR) assessed by the investigator to PD assessed by the investigator |
| Secondary | Treatment-emergent adverse events (TEAEs) and Laboratory results,physical examinations, or vital signs | Up to 2 years | Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AE's will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT). |
| Secondary | Determination of CA-125 response with GCIG criteria | Up to 2 years | GCIG CA-125 response rate will be calculated using the CA-125 Response-Evaluable population and its exact 95% CI will be estimated using the Clopper-Pearson method. |
| Secondary | PFS assessed by the BIRC | Up to 2 years | The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the BIRC, whichever occurs first. |
| Secondary | PFS assessed by the investigator | Up to 2 years | The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the investigator, whichever occurs first. |
| Secondary | Overall survival (OS) | Up to 2 years | The time interval from the first dose of IMGN853 to death |
| Secondary | Summary statistics of intact ADC, total Ab (TAb), DM4 and S-methyl DM4 concentration data over time | Up to 2 years | To assess the PK properties of IMGN853 and its key metabolites |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05622890
GET https://conductscience.org/api/trials/v1/NCT05622890/registered